On May 16, 2019 ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, reported that ALX148 clinical results have been selected for presentation in the Poster Discussion Session at the 2019 ASCO (Free ASCO Whitepaper) Annual Meeting, May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois (Press release, ALX Oncology, MAY 16, 2019, View Source [SID1234536443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALX148 Presentation Information

Title: A phase 1 study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy (Abstract #2514).

Poster Discussion Session: Developmental Immunotherapy and Tumor Immunobiology, Advances in Immune Checkpoint Inhibition

Date: Saturday, June 1

Time: 1:15 p.m. – 1:27 p.m.

Location: Hall D1

Poster Display Session: Developmental Immunotherapy and Tumor Immunobiology

Date: Saturday, June 1

Time: 8:00 a.m. – 11:00 a.m.

Location: Hall A